Protagonist Therapeutics
PTGX | NASDAQ
$124.83
-$6.12 (-4.67%)
At close: Nov 16, 2026, 4:00 PM ET
$122.34
-$2.49 (-1.99%)
After-hours:
Nov 16, 2026, 7:54 PM ET
Protagonist Therapeutics Company Profile
Company profile explainedCompany Profile
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Key Executives
| Name | Position |
|---|---|
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director |
| Asif Ali | Executive Vice President & Chief Financial Officer |
| Abha Bommireddi | Executive Vice President & Chief of Staff |
| Arturo Molina FACP | Chief Medical Officer |
| Ashok Bhandari | EVP & Chief Discovery Officer |
| Carena Spivey | Executive VP & Chief Human Resources Officer |
| Carter J. King | Executive Vice President of Business Development |
| Matthew Gosling | Executive Vice President and Chief Legal & Business Officer |
| Newman Yeilding | Executive Vice President, Chief Scientific Officer |
| Venkat Thalladi | EVP & Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 02, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | S-8 POS | Filing |
| Aug 05, 2026 | S-8 POS | Filing |
| Aug 05, 2026 | S-8 POS | Filing |
Protagonist Therapeutics
| Country | United States |
| IPO Date | Aug 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Dinesh V. Patel |
Contact Details
7707 Gateway Boulevard Newark,
California 94560 United States
Stock Details
| Ticker Symbol | PTGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001377121 |
| CUSIP Number | 74366E102 |
| ISIN Number | US74366E1029 |
| SIC Code | 2834 |
Recent News
- 16 hours ago / zacks.comHow Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%
- 11 days ago / zacks.comProtagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates
- 19 days ago / zacks.comProtagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
- 23 days ago / seekingalpha.comProtagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
- 1 month ago / zacks.comProtagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
- 2 months ago / seekingalpha.comProtagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- 3 months ago / seekingalpha.comProtagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
- 3 months ago / marketbeat.comProtagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
- 3 months ago / seekingalpha.comProtagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement
- 3 months ago / zacks.comSurging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Add to Watchlist
Select watchlists to add or remove PTGX